This research demonstrates sustained nitric oxide release from mesoporous silica nanoparticles, indicating potential for biomedical applications.
The exogenous delivery of nitric oxide (NO) as a therapeutic is challenging due to NO's high reactivity and short half-life. Owing to NO's many physiological functions, the development of NO-releasing materials for sustained and long-term NO delivery has been a focus of much research. Herein, we report the synthesis of an organosilane bestowing a tertiary thiol (3° SH) moiety derived from (3-aminopropyl)trimethoxysilane and N-acetyl-d-penicillamine thiolactone (NAP-thiolactone). The resulting tertiary thiol-bearing organosilanes (NAPTMS) were covalently tethered to mesoporous silica nanoparticles (MSNs) to generate 3° SH-enriched MSNs (MSN-NAP) that, when nitrosated, formed NO-releasing mesoporous silica nanoparticles (MSN-SNAP). The morphological and thermomechanical properties of MSN-NAP and MSN-SNAP proved suitable as potential therapeutic materials, with NO payloads (1.39 ± 0.15 μmol mg–1) approximately ten times greater than previously reported tertiary S-nitrosothiol (3° RSNO) systems. In contrast to other reports, MSN-SNAP exhibits a sustained NO-release profile for >24 h under physiological conditions. The MSN-SNAP thus represents a promising NO-releasing prodrug for various biomedical applications that require sustained NO delivery at low concentrations (pM to nM).
No takes yet. Share an insight, caveat, or question.
Kumar et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: